Journey Medical Corporation to Participate in October 2025 Investor Conferences Pharmaceutical Investing
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model Pharmaceutical Investing
Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing Biotech Investing
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer Biotech Investing
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® Biotech Investing
Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System Medical Device Investing
